Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Chronological effects of rifampicin discontinuation on cytochrome P450 activity in healthy Japanese volunteers, using the cocktail method.

Inui N, Akamatsu T, Uchida S, Tanaka S, Namiki N, Karayama M, Chida K, Watanabe H.

Clin Pharmacol Ther. 2013 Dec;94(6):702-8. doi: 10.1038/clpt.2013.167. Epub 2013 Aug 23.

PMID:
23974699
2.

Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".

Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R, Kearns GL, Bertino JS Jr.

Clin Pharmacol Ther. 2000 Oct;68(4):375-83.

PMID:
11061577
3.

Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.

Turpault S, Brian W, Van Horn R, Santoni A, Poitiers F, Donazzolo Y, Boulenc X.

Br J Clin Pharmacol. 2009 Dec;68(6):928-35. doi: 10.1111/j.1365-2125.2009.03548.x.

4.

Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.

Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ Jr, Klein CE, Rublein JC, Kashuba AD.

J Acquir Immune Defic Syndr. 2006 May;42(1):52-60.

PMID:
16639344
5.

Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults.

Armani S, Ting L, Sauter N, Darstein C, Tripathi AP, Wang L, Zhu B, Gu H, Chun DY, Einolf HJ, Kulkarni S.

Clin Drug Investig. 2017 May;37(5):465-472. doi: 10.1007/s40261-017-0497-0.

6.

Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects.

Chen XP, Tan ZR, Huang SL, Huang Z, Ou-Yang DS, Zhou HH.

Clin Pharmacol Ther. 2003 Mar;73(3):264-71.

PMID:
12621391
7.

Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.

Bosilkovska M, Samer C, Déglon J, Thomas A, Walder B, Desmeules J, Daali Y.

Basic Clin Pharmacol Toxicol. 2016 Sep;119(3):284-90. doi: 10.1111/bcpt.12586. Epub 2016 Apr 25.

PMID:
27009433
8.

Effect of commercial Rhodiola rosea on CYP enzyme activity in humans.

Thu OK, Spigset O, Nilsen OG, Hellum B.

Eur J Clin Pharmacol. 2016 Mar;72(3):295-300. doi: 10.1007/s00228-015-1988-7. Epub 2015 Nov 28.

PMID:
26613955
9.

Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots.

Bosilkovska M, Samer CF, Déglon J, Rebsamen M, Staub C, Dayer P, Walder B, Desmeules JA, Daali Y.

Clin Pharmacol Ther. 2014 Sep;96(3):349-59. doi: 10.1038/clpt.2014.83. Epub 2014 Apr 10.

10.

In vivo modulation of CYP enzymes by quinidine and rifampin.

Branch RA, Adedoyin A, Frye RF, Wilson JW, Romkes M.

Clin Pharmacol Ther. 2000 Oct;68(4):401-11.

PMID:
11061580
11.

Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".

Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba AD, Rowland E, Bertino JS Jr.

Clin Pharmacol Ther. 2003 Nov;74(5):437-47.

PMID:
14586384
12.

High-sensitivity liquid chromatography-tandem mass spectrometry for the simultaneous determination of five drugs and their cytochrome P450-specific probe metabolites in human plasma.

Oh KS, Park SJ, Shinde DD, Shin JG, Kim DH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 May 1;895-896:56-64. doi: 10.1016/j.jchromb.2012.03.014. Epub 2012 Mar 19.

PMID:
22483397
13.

Impact of visceral leishmaniasis and curative chemotherapy on cytochrome P450 activity in Brazilian patients.

Lanchote VL, Almeida R, Barral A, Barral-Netto M, Marques MP, Moraes NV, da Silva AM, Souza TM, Suarez-Kurtz G.

Br J Clin Pharmacol. 2015 Nov;80(5):1160-8. doi: 10.1111/bcp.12677. Epub 2015 Jul 2.

14.

Effects of Angelicae tenuissima radix, Angelicae dahuricae radix and Scutellariae radix extracts on cytochrome P450 activities in healthy volunteers.

Yi S, Cho JY, Lim KS, Kim KP, Kim J, Kim BH, Hong JH, Jang IJ, Shin SG, Yu KS.

Basic Clin Pharmacol Toxicol. 2009 Oct;105(4):249-56. doi: 10.1111/j.1742-7843.2009.00423.x. Epub 2009 May 5.

15.

Simultaneous and comprehensive in vivo analysis of cytochrome P450 activity by using a cocktail approach in rats.

Uchida S, Tanaka S, Namiki N.

Biopharm Drug Dispos. 2014 May;35(4):228-36. doi: 10.1002/bdd.1888. Epub 2014 Feb 4.

PMID:
24395703
16.

Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo.

Ryu JY, Song IS, Sunwoo YE, Shon JH, Liu KH, Cha IJ, Shin JG.

Clin Pharmacol Ther. 2007 Nov;82(5):531-40. Epub 2007 Mar 28. Erratum in: Clin Pharmacol Ther. 2010 Aug;88(2):275. Dosage error in article text.

PMID:
17392720
17.

Cytochrome P450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction.

Haas CE, Brazeau D, Cloen D, Booker BM, Frerichs V, Zaranek C, Frye RF, Kufel T.

Eur J Clin Pharmacol. 2005 Sep;61(8):583-93. Epub 2005 Jul 22.

PMID:
16041547
18.

Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.

Walzer M, Bekersky I, Blum RA, Tolbert D.

Pharmacotherapy. 2012 Apr;32(4):340-53. doi: 10.1002/j.1875-9114.2012.01028.x. Epub 2012 Mar 15.

PMID:
22422635
19.

Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis.

Jenkins J, Williams D, Deng Y, Collins DA, Kitchen VS.

Eur J Clin Pharmacol. 2010 Jan;66(1):67-76. doi: 10.1007/s00228-009-0716-6. Epub 2009 Sep 16.

PMID:
19756558
20.

A high-throughput assay using liquid chromatography-tandem mass spectrometry for simultaneous in vivo phenotyping of 5 major cytochrome p450 enzymes in patients.

Ghassabian S, Chetty M, Tattam BN, Chem MC, Glen J, Rahme J, Stankovic Z, Ramzan I, Murray M, McLachlan AJ.

Ther Drug Monit. 2009 Apr;31(2):239-46. doi: 10.1097/FTD.0b013e318197e1bf.

PMID:
19307938

Supplemental Content

Support Center